Table 1 Correlation of demographic, clinico-pathological parameters of breast cancer patients with mean percentage of CD3⁺, CD8⁺ and CD45RO⁺ T lymphocytes

Age

0.27

0.30

0.37

 < 50

18 (47.4 %)

15.1 (10.2)

39.1 (23.6)

34.6 (30.9)

 50+

20 (52.6 %)

19.7 (12.2)

48.0 (26.7)

42.6 (22.6)

 Female

43 (100.0 %)

16.7 (11.3)

43.2 (25.3)

38.2 (26.1)

Diagnosis

0.09

0.35

0.24

 IDC

38 (88.4 %)

18.1 (11.1)

44.1 (25.3)

36.5 (26.8)

 ILC

3 (7.0 %)

4.5 (2.3)

50.0 (26.2)

62.7 (3.1)

 Others

2 (4.7 %)

10.5 (13.4)

18.5 (19.1)

33.0 (7.1)

Grade

0.48

0.14

0.44

 1

5 (11.6 %)

11.0 (6.9)

33.2 (25.2)

38.4 (19.0)

 2

23 (53.5 %)

18.0 (9.9)

50.4 (26.2)

42.5 (25.2)

 3

15 (34.9 %)

16.9 (14.0)

34.9 (21.3)

31.0 (29.6)

LVI

0.39

0.12

0.21

 Positive

18 (41.9 %)

14.9 (11.5)

36.1 (25.8)

32.3 (28.6)

 Negative

25 (58.1 %)

18.0 (11.2)

48.5 (24.0)

42.6 (23.8)

Lymph node

0.29

0.04

0.32

 Positive

19 (63.3 %)

17.7 (10.1)

47.9 (28.2)

41.5 (28.1)

 Negative

11 (36.7 %)

13.3 (11.1)

30.6 (13.8)

30.7 (27.1)

Estrogen receptor

0.086

0.87

0.74

 Positive

25 (58.1 %)

13.8 (7.3)

42.7 (26.4)

37.0 (22.4)

 Negative

18 (41.9 %)

20.7 (14.5)

44.0 (24.4)

39.9 (31.4)

Progesterone receptor

0.086

0.87

0.74

 Positive

25 (58.1 %)

13.8 (7.3)

42.7 (26.4)

37.0 (22.4)

 Negative

18 (41.9 %)

20.7 (14.5)

44.0 (24.4)

39.9 (31.4)

HER2/neu

0.006

0.83

0.56

 Positive

11 (25.6 %)

24.5 (13.5)

44.7 (25.0)

33.9 (26.3)

 Negative

32 (74.4 %)

13.8 (9.0)

42.7 (25.8)

39.5 (26.3)

Molecular subtype

0.034

0.48

0.82

 Luminal A^a

23 (53.5 %)

13.5 (7.4)

44.7 (26.7)

37.3 (23.3)

 Luminal B^b

2 (4.7 %)

17.0 (8.5)

21.5 (9.2)

34.0 (5.7)

 TNBC^c

9 (20.9 %)

14.5 (13.0)

38.2 (24.3)

45.3 (33.6)

 HER2/neu Positive^d

9 (20.9 %)

26.1 (14.2)

50.5 (24.5)

33.9 (29.8)